GRThe article discusses the delay in providing compensation for new biomarkers required for monitoring ovarian cancer treatments. A typographical error in an October 2025 ministerial decision has led to the exclusion of hundreds of women with ovarian cancer from receiving this compensation. Patients are waiting up to nine months for the critical reimbursement, which covers essential tests needed for treatment monitoring and guidance. The National Health Services Provision Organization (EOPPY) states that negotiations with diagnostic centers are ongoing, but patients report feeling desperate as their condition does not wait. Some patients have been waiting over six months and face costs of up to 600 euros.
Bias read (Center): The article presents the issue of delayed compensation for medical services as a bureaucratic problem rather than taking a clear ideological stance. It reports on the situation without overtly criticizing either the government or opposition, focusing on the administrative challenges faced by the EOP
